(Q36844906)

16 August 2017

1 reference

title

Troxacitabine in acute leukemia (English)

1 reference

16 August 2017

Swords R

1

1 reference

16 August 2017

Giles F

series ordinal

2

1 reference

16 August 2017

publication date

1 June 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

12

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

219-227

1 reference

Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Troxacitabine-based therapy of refractory leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Some nucleoside analogs with anti-human immunodeficiency virus activity inhibit replication of Epstein-Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

A novel action of human apurinic/apyrimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3' termini of DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Troxacitabine activity in extramedullary myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

Pyridoxine for the palmar-plantar erythrodysesthesia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330701406881

10.1080/10245330701406881

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference